In vitro activity of azithromycin against nontyphoidal Salmonella enterica

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3498-3501

  Gunell, Marianne ^a   Kotilainen, Pirkko ^b   Jalava, Jari ^a   Huovinen, Pentti ^a   Siitonen, Anja ^a   Hakanen, Antti J ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; FINLAND; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLOSIS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FINLAND; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; SALMONELLA ENTERICA; SALMONELLA INFECTIONS;

EID: 77955375156     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01678-09     Document Type: Article

References (31)

1. Aarestrup, F. M., C. Wiuff, K. Molbak, and E. J. Threlfall. 2003. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob. Agents Chemother. 47:827-829.
2. Braoudaki, M., and A. C. Hilton. 2005. Mechanisms of resistance in Salmonella enterica adapted to erythromycin, benzalkonium chloride and triclosan. Int. J. Antimicrob. Agents 25:31-37.
3. Butler, T. 2001. Effect of increased inoculum of Salmonella typhi on MIC of azithromycin and resultant growth characteristics. J. Antimicrob. Chemother. 48:903-906.
4. Caldwell, D. B., Y. Wang, and J. Lin. 2008. Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni. Antimicrob. Agents Chemother. 52:3947-3954.
5. Cattoir, V., L. Poirel, V. Rotimi, C. J. Soussy, and P. Nordmann. 2007. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J. Antimicrob. Chemother. 60:394-397.
6. Cavaco, L. M., R. S. Hendriksen, and F. M. Aarestrup. 2007. Plasmid-mediated quinolone resistance determinant qnrS1 detected in Salmonella enterica serovar Corvallis strains isolated in Denmark and Thailand. J. Antimicrob. Chemother. 60:704-706.
7. Chinh, N. T., C. M. Parry, N. T. Ly, H. D. Ha, M. X. Thong, T. S. Diep, J. Wain, N. J. White, and J. J. Farrar. 2000. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob. Agents Chemother. 44:1855-1859.
8. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 7th edition, M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement, M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Doublet, B., S. A. Granier, F. Robin, R. Bonnet, L. Fabre, A. Brisabois, A. Cloeckaert, and F. X. Weill. 2009. Novel plasmid-encoded ceftazidime- hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. Antimicrob. Agents Chemother. 53:1944-1951.
11. DuPont, H. L. 2009. Clinical practice. Bacterial diarrhea. N. Engl. J. Med. 361:1560-1569.
12. Frenck, R. W., Jr., A. Mansour, I. Nakhla, Y. Sultan, S. Putnam, T. Wierzba, M. Morsy, and C. Knirsch. 2004. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin. Infect. Dis. 38:951-957.
13. Girgis, N. I., T. Butler, R. W. Frenck, Y. Sultan, F. M. Brown, D. Tribble, and R. Khakhria. 1999. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob. Agents Chemother. 43:1441-1444.
14. Gunell, M., M. A. Webber, P. Kotilainen, A. J. Lilly, J. M. Caddick, J. Jalava, P. Huovinen, A. Siitonen, A. J. Hakanen, and L. J. Piddock. 2009. Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. Antimicrob. Agents Chemother. 53:3832-3836.
15. Haanperä, M., P. Huovinen, and J. Jalava. 2005. Detection and quantification of macrolide resistance mutations at positions 2058 and 2059 of the 23S rRNA gene by pyrosequencing. Antimicrob. Agents Chemother. 49:457-460.
16. Hakanen, A., P. Kotilainen, P. Huovinen, H. Helenius, and A. Siitonen. 2001. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg. Infect. Dis. 7:996-1003.
17. Hakanen, A., P. Kotilainen, J. Jalava, A. Siitonen, and P. Huovinen. 1999. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J. Clin. Microbiol. 37:3572-3577.
18. Hakanen, A. J., P. Kotilainen, S. Pitkanen, S. Huikko, A. Siitonen, and P. Huovinen. 2006. Reduction in fluoroquinolone susceptibility among nontyphoidal strains of Salmonella enterica isolated from Finnish patients. J. Antimicrob. Chemother. 57:569-572.
19. Hakanen, A. J., M. Lindgren, P. Huovinen, J. Jalava, A. Siitonen, and P. Kotilainen. 2005. New quinolone resistance phenomenon in Salmonella enterica: nalidixic acid-susceptible isolates with reduced fluoroquinolone susceptibility. J. Clin. Microbiol. 43:5775-5778.
20. Hopkins, K. L., M. Day, and E. J. Threlfall. 2008. Plasmid-mediated quinolone resistance in Salmonella enterica, United Kingdom. Emerg. Infect. Dis. 14:340-342.
21. Lavilla, S., J. J. Gonzalez-Lopez, M. Sabate, A. Garcia-Fernandez, M. N. Larrosa, R. M. Bartolome, A. Carattoli, and G. Prats. 2008. Prevalence of qnr genes among extended-spectrum beta-lactamase-producing enterobacterial isolates in Barcelona, Spain. J. Antimicrob. Chemother. 61:291-295.
22. Lindgren, M. M., P. Kotilainen, P. Huovinen, S. Hurme, S. Lukinmaa, M. A. Webber, L. J. Piddock, A. Siitonen, and A. J. Hakanen. 2009. Reduced fluoroquinolone susceptibility in Salmonella enterica isolates from travelers, Finland. Emerg. Infect. Dis. 15:809-812.
23. Lukinmaa, S., U. M. Nakari, A. Liimatainen, and A. Siitonen. 2006. Genomic diversity within phage types of Salmonella enterica ssp. enterica serotypes Enteritidis and Typhimurium. Foodborne Pathog. Dis. 3:97-105.
24. Nyberg, S. D., M. Osterblad, A. J. Hakanen, P. Huovinen, and J. Jalava. 2007. Detection and molecular genetics of extended-spectrum beta-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates from Finland, 2002-2004. Scand. J. Infect. Dis. 39:417-424.
25. Parry, C. M., V. A. Ho, T. Phuong le, P. V. Bay, M. N. Lanh, T. Tung le, N. T. Tham, J. Wain, T. T. Hien, and J. J. Farrar. 2007. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob. Agents Chemother. 51:819-825.
26. Pfister, P., S. Jenni, J. Poehlsgaard, A. Thomas, S. Douthwaite, N. Ban, and E. C. Bottger. 2004. The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059. J. Mol. Biol. 342:1569-1581.
27. Poirel, L., J. D. Pitout, L. Calvo, J. M. Rodriguez-Martinez, D. Church, and P. Nordmann. 2006. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. Antimicrob. Agents Chemother. 50:1525-1527.
28. Stevenson, J. E., K. Gay, T. J. Barrett, F. Medalla, T. M. Chiller, and F. J. Angulo. 2007. Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob. Agents Chemother. 51:195-197.
29. Stock, I., and B. Wiedemann. 2000. Natural antibiotic susceptibility of Salmonella enterica strains. Int. J. Antimicrob. Agents 16:211-217.
30. Threlfall, E. J., E. de Pinna, M. Day, J. Lawrence, and J. Jones. 2008. Alternatives to ciprofloxacin use for enteric fever, United kingdom. Emerg. Infect. Dis. 14:860-861.
31. Tribble, D. R., J. W. Sanders, L. W. Pang, C. Mason, C. Pitarangsi, S. Baqar, A. Armstrong, P. Hshieh, A. Fox, E. A. Maley, C. Lebron, D. J. Faix, J. V. Lawler, G. Nayak, M. Lewis, L. Bodhidatta, and D. A. Scott. 2007. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin. Infect. Dis. 44:338-346.